# Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts

> **NCT04467671** · PHASE2 · RECRUITING · sponsor: **Nationwide Children's Hospital** · enrollment: 24 (estimated)

## Conditions studied

- HLH - Hypoplastic Left Heart Syndrome
- DORV
- DILV - Double Inlet Left Ventricle
- Mitral Atresia
- Tricuspid Atresia
- Unbalanced AV Canal
- Single-ventricle
- Heart Defects, Congenital
- Cardiovascular Abnormalities
- Cardiovascular Diseases
- Heart Diseases

## Interventions

- **COMBINATION_PRODUCT:** Tissue Engineered Vascular Grafts

## Key facts

- **NCT ID:** NCT04467671
- **Lead sponsor:** Nationwide Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-07-15
- **Primary completion:** 2026-08
- **Final completion:** 2027-08
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-06-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04467671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04467671, "Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04467671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*